Mirzaten Q-Tab (Mirtazapine)

Mirtazapine, the active ingredient in Mirzaten Q-Tab, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It treats major depressive disorder in adults. GNH USA supplies Mirzaten Q-Tab as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is indicated for depressive disorders and related conditions. - Major depressive disorder: alleviates depressive symptoms and improves mood. - Depressive episodes with prominent insomnia: helps restore sleep while treating depression. - Depression with significant anxiety: reduces anxiety symptoms alongside antidepressant effect.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior, especially early in treatment - Severe hypotension or syncope - Hepatic dysfunction or hepatitis - Seizures

Before initiating therapy, clinicians should consider several safety aspects. - Hepatic function: assess liver enzymes in patients with liver disease. - Suicidal risk: monitor for emergent suicidal thoughts, particularly in the first weeks. - Elderly patients: use caution due to increased sedation and fall risk. - Discontinuation: avoid abrupt cessation to reduce withdrawal symptoms. - Concomitant CNS depressants: evaluate additive sedative effects. - Store at ambient temperature: keep in the original pack, protect from moisture.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): heightened serotonin syndrome potential. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors or inducers (e.g., ketoconazole, rifampin): may alter drug exposure. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation. - Antihistamines: increased drowsiness. - Warfarin: monitor INR for possible anticoagulant effect changes. - Lithium: watch for enhanced neurotoxic signs.